https://www.selleckchem.com/pr....oducts/apx-115-free-
The sustained high group experienced shorter exacerbation-free survival and more frequent exacerbations than the sustained low group (median number of exacerbation events, 3 vs 0, p = 0.01). In the intermediate group, the high CV group experienced shorter exacerbation-free survival than the low CV group, and the CV of FENO was an independent contributing factor to the development of exacerbations. Persistence of FENO above 50 ppb over the years as well as the presence of large variations in FENO levels was associated with the
Beğen
Yorum Yap
Paylaş
